Literature DB >> 22843625

The clinical application of 4D 18F-FDG PET/CT on gross tumor volume delineation for radiotherapy planning in esophageal squamous cell cancer.

Yao-Ching Wang1, Te-Chun Hsieh, Chun-Yen Yu, Kuo-Yang Yen, Shang-Wen Chen, Shih-Neng Yang, Chun-Ru Chien, Shih-Ming Hsu, Tinsu Pan, Chia-Hung Kao, Ji-An Liang.   

Abstract

A combination of four-dimensional computed tomography with (18)F-fluorodeoxyglucose positron emission tomography (4D CT-FDG PET) was used to delineate gross tumor volume (GTV) in esophageal cancer (EC). Eighteen patients with EC were prospectively enrolled. Using 4D images taken during the respiratory cycle, the average CT image phase was fused with the average FDG PET phase in order to analyze the optimal standardized uptake values (SUV) or threshold. PET-based GTV (GTV(PET)) was determined with eight different threshold methods using the auto-contouring function on the PET workstation. The difference in volume ratio (VR) and conformality index (CI) between GTV(PET) and CT-based GTV (GTV(CT)) was investigated. The image sets via automatic co-registrations of 4D CT-FDG PET were available for 12 patients with 13 GTV(CT) values. The decision coefficient (R(2)) of tumor length difference at the threshold levels of SUV 2.5, SUV 20% and SUV 25% were 0.79, 0.65 and 0.54, respectively. The mean volume of GTV(CT) was 29.41 ± 19.14 ml. The mean VR ranged from 0.30 to 1.48. The optimal VR of 0.98, close to 1, was at SUV 20% or SUV 2.5. The mean CI ranged from 0.28 to 0.58. The best CI was at SUV 20% (0.58) or SUV 2.5 (0.57). The auto-contouring function of the SUV threshold has the potential to assist in contouring the GTV. The SUV threshold setting of SUV 20% or SUV 2.5 achieves the optimal correlation of tumor length, VR, and CI using 4D-PET/CT images.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22843625      PMCID: PMC3393356          DOI: 10.1093/jrr/rrs009

Source DB:  PubMed          Journal:  J Radiat Res        ISSN: 0449-3060            Impact factor:   2.724


INTRODUCTION

The use of 18fluoro-deoxyglucose positron emission tomography (18F-FDG PET) supplements the interdisciplinary process of radiotherapy (RT) by including information on the biological status of tumors, which is complementary to conventional computed tomography (CT) images and may change the tumor volume delineation [1]. RT is an important part of the multidisciplinary approach to treating esophageal cancer (EC), but tumor control and overall survival do not always improve [2]. 18F-FDG PET has been shown to improve the staging of EC [3, 4]. Several studies suggest that overlaying PET images on CT images has some impact on the definition of the gross tumor volume (GTV), decreases inter-observer variability and, thus, changes treatment planning [5-7]. However, when radiation oncologists contour the GTVs on a fused PET and CT image or an integrated PET/CT image, the problem of setting an appropriate threshold for the PET arises. Because several investigations have found that auto-contouring or manual contouring of PET-based tumor volume results in a change of the GTV compared with CT-based GTV [8-10], standards should be set for PET/CT-based tumor delineation. The published methods are based on a threshold determined by the percentage of the maximal standardized uptake value (SUVmax) using values ranging from 15 to 50% for non-small cell lung cancer (NSCLC) [11-13]. Great variation has been found in the validated standardized methods for EC in setting this threshold [6, 14–16]; these include using mean activity in the liver plus various standard deviations, the various absolute standardized uptake values (SUV) (GTV = SUV of ≥2) or using percentages of the SUVmax (GTV = volume encompassed by ≥25% the SUVmax). During a free breathing cycle, organ or tumor motion always influences the accuracy and quality of CT images in thoracic malignancies including EC. The extent of tumor motion and different spatial tumor positions should be carefully considered when using four-dimensional (4D) CT as described in NSCLC [17, 18]. A recent study reported that EC moved substantially during the respiratory cycle, especially in the cranial–caudal direction of the lower third portion of the esophagus [19]. Although the real benefits of clinical outcomes need further investigation, respiratory 4D-PET/CT techniques are highly useful in targeting volume definitions, which are accurately representative of organ and lesion motion [20]. The feasibility of implementing 4D-PET/CT in determining the GTV for EC is still unknown. Thus, there is a need to perform a pilot study using 4D-PET/CT for contouring. We hypothesized that some standards could be obtained when defining GTV for EC using the biological target volume from 4D-PET/CT images. We performed this prospective study to evaluate the feasibility of 4D-PET/CT simulations in RT planning for EC. Additionally, the appropriateness of the percentage threshold method was investigated to determine the best volumetric match between PET-based and CT-based GTV when contouring the primary tumor volume of EC.

MATERIALS AND METHODS

Patients

This study was a prospective analysis, approved by the local institutional review board (DMR98-IRB-171), of 4D-PET/CT in RT planning of EC. Patients with histologically approved EC who were scheduled to undergo definitive RT, concurrent chemoradiotherapy or radical surgery, were eligible for this study. Eighteen patients with esophageal squamous cell cancer were enrolled between December 2009 and January 2011. The image data from 12 patients with 13 GTVCT were available for analysis in this study. The median age was 48.5 years (range 38–76 years). All patients were male. Table 1 presents the characteristics of these patients.
Table 1.

Patient characteristics

CharacteristicPatients (n)
Tumor locationa
  Upper-middle2
  Middle3
  Lower8
Clinical stageb
 Tumor stage
  T11
  T21
  T310
  T41
 Nodal stage
  N03
  N110
 Metastasis stage
  M010
  Mx2c
Endoscopic ultrasonography9 (75%)
CT based tumor length (cm)1.75–10.00 (median 5.5)
Mean5.73 ± 2.40
CT based tumor volume (cm3)3.65–70.76 (median 24.95)
Mean29.41 ± 19.14
SUVmaxd13.26 ± 2.78 (median 13.2)

a One patient with two separate tumors at middle and lower third.

b AJCC cancer staging, 6th, 2002.

c Two patients had small individual hypermetabolic lesions at the left lower lung.

d SUVmax: maximal of standardized uptake value.

Patient characteristics a One patient with two separate tumors at middle and lower third. b AJCC cancer staging, 6th, 2002. c Two patients had small individual hypermetabolic lesions at the left lower lung. d SUVmax: maximal of standardized uptake value.

PET-CT image acquisition

All patients were asked to fast for at least 4 h before 18F-FDG PET/CT imaging. Each of them received 370 MBq (10 mCi) of 18F-FDG intravenously 40 min before scanning and rested in a supine position in a quiet and dimly lit room. All images were acquired with an integrated PET/CT scanner (Discovery STE, GE Medical Systems, Milwaukee, WI, USA). The patient's arms were elevated above their head. First, whole-body PET/CT images were taken according to the standardized protocol. The CT images were reconstructed onto a 512 × 512 matrix and converted to a 128 × 128 matrix, with 511-keV-equivalent attenuation factors for attenuation correction of the corresponding PET emission images. Immediately after finishing the whole-body PET/CT images, patients were repositioned and placed in a simulated RT planning position using the Real-time Position Management (RPM) system respiratory gating hardware (Varian Medical Systems Inc., Palo Alto, CA, USA). 4D-CT images with 2.50-mm slice thickness, and 4D-PET images with two table positions, 7 min per position, were acquired. The respiration cycle was divided into 10 phases. All CT images were automatically sorted using 4D software (Advantage 4D, GE Healthcare). The images were transferred from the PET/CT workstation via DICOM3 to the RTP (Eclipse version 8.6, Varian Medical Systems Inc.) for GTV delineation. All phases of CT images and PET images were automatically fused for this gating study. PET/CT-based GTV of the primary tumor (GTVPET) was defined by the auto-contouring function at the AW workstation (Advantage SimTM 7.6.0, GE Healthcare), either by applying the isodensity volumes and adjusting the different percentages to the maximum threshold levels, or by simply using a fixed value of SUV. The threshold strategies for assessing the optimized SUV for GTV contouring were derived from the results of other studies [6, 7, 15, 21]. Eight different threshold methods were used in this study. They were SUV 15%, SUV 2, SUV 2.5, SUV 20%, SUV 25%, SUV30 %, SUV 40% and SUV 50%. The length of the GTVPET provided by the auto-contouring function was not changed at all. All the artifacts within the GTVPET, including the areas overlaid by the heart, bone and great vessels, were excluded manually in the RTP system (Fig. 1).
Fig. 1.

(A) An example of modification of autocontouring gross tumor volume (GTV) on a standard uptake value of 15% (SUV 15%); (B) Comparison of the GTV on CT (in red) and GTV on SUV 20% (in green) in axial, coronal, and sagittal views.

(A) An example of modification of autocontouring gross tumor volume (GTV) on a standard uptake value of 15% (SUV 15%); (B) Comparison of the GTV on CT (in red) and GTV on SUV 20% (in green) in axial, coronal, and sagittal views.

CT-based GTV definition

The temporal resolution of PET is an average of several respiratory cycles. In contrast to helical CT, the temporal resolution of averaged CT (ACT) is comparable with that of PET. Furthermore, Chi et al. [22] demonstrated that respiration artifacts in PET from PET/CT can be minimized using ACT, and ACT is temporally and spatially consistent with PET. On the basis of axial ACT images, contouring of the tumor volume and critical structures was performed without knowing the PET results in an effort to decrease bias. Information about the tumor extent from the contrast CT scan, panendoscopy and endoscopic ultrasonography (EUS) was used when delineating the GTVCT. Excluding the adjacent metastatic lymph nodes, the volume of primary tumors (GTVCT) was contoured as a reference tumor volume. To reduce inter-observer variations, at least two different radiation oncologists carried out the contouring of the tumors for each patient.

Conformality index and volume ratio comparison

After completion of the GTVCT contouring in the RTP system, the radiation oncologists reviewed the consistency of PET/CT images with nuclear medicine physicians. The volume of GTVCT and GTVPET was compared using the conformality index (CI) [23] and volume ratio (VR). The CI is the ratio of the volume of intersection of two volumes (A ∩ B) compared with the volume of union of the two volumes (A ∪ B) under comparison () [21, 24]. Volume ratio is the ratio of two volumes, and the denominator is the volume of GTVCT. A suitable threshold level could be defined when GTVPET was observed to be the best fit of the length, CI, or VR from the GTVCT.

Statistical analysis

All statistical tests were performed using SPSS 15 (SPSS, Chicago, IL, USA), and each GTV was analyzed by one-way ANOVA with Scheffe's post hoc test. P-values of 0.05 or less were considered statistically significant. Pearson's correlation was performed to assess the correlation between tumor length evaluated by GTVCT with that by GTVPET. Possible values for the decision coefficients (R2) range from 0 to 1, with values closer to 1 indicating a regression line with high correlation.

RESULTS

Of the 18 patients, automatic co-registrations of 4D-PET/CT were successful in 13 tumors from 12 patients. In six patients, the fused images were not available for analysis. One had a small T1 tumor, which was undetectable on PET scans. The SUVmax was 2.96 in another patient with a T1 lesion, and therefore, this was not suitable for further analysis. Because of the different table positions between 4D-PET and 4D-CT, fusion failure occurred in the first patient enrolled in this study. The other two patients excluded had irregular respiratory rhythms, which caused a failure in the image fusion. Diffuse lung and bone metastatic status caused another patient to be excluded. The auto-contouring function for GTVPET was insufficient for primary GTV delineation. Table 1 summarizes the characteristics of the 13 patients with successful automatic co-registrations of 4D-PET/CT. For all of these patients, the histological type was squamous cell carcinoma. The median age was 48.5 years (range, 38–76 years). Eleven lesions (85%) were either T3 or T4 stage. EUS was performed on nine patients (75%). The mean length of GTVCT was 5.73 ± 2.40 cm (range, 1.75–10.00 cm). The mean volume of GTVCT was 29.41 ± 19.14 ml (range, 3.65–70.76 ml). The mean SUVmax was 13.26 ± 2.78 (range, 9.4–16.9). Figure 2 shows the results of the mean tumor lengths on CT (CTlength) and the mean tumor length by different SUV thresholds (PETlength). Figure 3 illustrates the correlation of CTlength compared with PETlength at SUV 2.5, SUV 20% and SUV 25%. The decision coefficients (R[2]) of tumor length difference at the threshold levels of SUV 2.5, SUV 20% and SUV 25% were 0.79, 0.65, and 0.54, respectively. The mean VR ranged from 0.30 to 1.48 (0.86 ± 0.24) (F = 29.34, P < 0.001). Figure 4 shows the mean VR at different SUV threshold levels. The VR values gradually decreased from SUV 15% to SUV 50%. The best fit for VR was found at SUV 20% (mean SUV 2.65 ± 0.56) and SUV 2.5, which achieved the optimal VR values of 0.98 ± 0.24 and 0.98 ± 0.26, respectively. The VR values at SUV 40% (0.41 ± 0.14) or SUV 50% (0.30 ± 0.12) were not at an ideal threshold level for GTV contouring of EC. The mean CIs ranged from 0.29 to 0.58 (F = 11.34, P < 0.001). Figure 5 displays the mean CI at different SUV threshold levels. The best fit for CI was at SUV 20% (0.58 ± 0.10) or SUV 2.5 (0.57 ± 0.13).
Fig. 2.

Mean tumor length as delineated on average computed tomography (CT) and on positron emission tomography (PET) obtained by eight standard uptake values (SUV) of interest. SUVn = SUV of n; SUV n% = n% of maximum SUV. Error bars indicate standard deviation.

Fig. 3.

Relationship between tumor length on average computed tomography (CT) and on positron emission tomography (PET) of standard uptake value (SUV) 2.5, SUV 20% and SUV 25%.

Fig. 4.

Mean volume ratios of eight SUVs of interest. Error bars indicate standard deviation. All SUV thresholds are compared with SUV 2.5, the P values of SUV 15%, SUV 40%, and SUV 50% are 0.005, 0.001 and 0.000, respectively.

Fig. 5.

Mean conformality index of eight standard uptake values (SUV) of interest. Error bars indicate standard deviation. All SUV thresholds are compared with SUV 20%; the P values of SUV 40% and SUV 50% are 0.004 and 0.000, respectively.

Mean tumor length as delineated on average computed tomography (CT) and on positron emission tomography (PET) obtained by eight standard uptake values (SUV) of interest. SUVn = SUV of n; SUV n% = n% of maximum SUV. Error bars indicate standard deviation. Relationship between tumor length on average computed tomography (CT) and on positron emission tomography (PET) of standard uptake value (SUV) 2.5, SUV 20% and SUV 25%. Mean volume ratios of eight SUVs of interest. Error bars indicate standard deviation. All SUV thresholds are compared with SUV 2.5, the P values of SUV 15%, SUV 40%, and SUV 50% are 0.005, 0.001 and 0.000, respectively. Mean conformality index of eight standard uptake values (SUV) of interest. Error bars indicate standard deviation. All SUV thresholds are compared with SUV 20%; the P values of SUV 40% and SUV 50% are 0.004 and 0.000, respectively.

DISCUSSION

This work was a pilot study to investigate the feasibility of 4D-PET/CT when contouring the GTV for EC. By comparing eight different threshold levels, the results revealed that GTVPET using a threshold setting of SUV 20% or SUV 2.5 correlated well with tumor length, VR and CI of GTVCT. The results were comparable with previous studies that investigated the optimal contouring threshold using non-respiratory controlled PET or PET/CT [5, 7, 15, 21]. Zhong et al. [15] found the FDG GTVPET at SUV 2.5 provided the closest estimation of gross tumor length in EC. Han et al. [7] investigated the combined 18F-fluorothymidine (FLT) and FDG PET/CT in assessing the feasibility of GTV delineation in EC and found a threshold setting of SUV 1.4 on FLT PET/CT, and SUV 2.5 on FDG PET/CT correlated well with the pathologic GTV length. When using a threshold level of SUV 40%, the PET-based tumor length was estimated to be smaller than the pathological length [7, 15]. Similarly, on the basis of the results of our study, an SUV threshold setting of ≤30% is not sufficient for auto-contouring. Panendoscopy, EUS, and CT images were usually used to obtain information regarding the precise tumor location and volume to optimize the GTV contouring for EC. However, neither the panendoscope nor EUS could pass through the obstructive lumen in locally advanced tumors. In this situation, the actual location of the distal margin of the tumor should be assessed using the CT image only. However, the precise tumor length and extent are not always discernible because a CT scan might not visualize mucosal or submucosal lesions. Konski et al. [5] reported that the EUS finding correlated better with PET-based tumor length than with CT scans in a series of 25 patients. The International Atomic Energy Agency expert group concluded that 18F-FDG PET/CT provides the best available imaging for accurate target delineation in RT planning [25]. With the implementation of PET/CT, the risk of geographic miss, underdosing and normal tissue complications may be decreased [9]. Certainly, the use of FDG-PET/CT for GTV delineation in RT planning should be validated on the basis of locoregional control and survival in the future [26]. 4D-CT in target volume delineation and motion has been well studied in NSCLC, including by fractionated RT and stereotactic RT [17, 18], but there have been few investigations of esophageal motility during RT. Dieleman et al. [27] reported a retrospective study analyzing 29 patients with nonesophageal cancer, mostly stage 1 lung cancer, using 4D-CT. They suggested that the distal esophagus had the largest motion margins of 9 mm in the mediolateral direction and 8 mm in the dorsoventral direction. Generally, patients undergoing PET are in a free breathing state and are not holding their breath or using respiratory gating techniques, and thus, the PET image is an average obtained during several respiratory cycles. Therefore, FDG quantification, tumor margin definition and detection of smaller tumors can be improved by the application of respiratory gating or 4D-PET [23, 28]. Chi et al. [22] demonstrated that respiratory artifacts in PET from PET/CT could be minimized using ACT, and ACT was temporally and spatially consistent with PET. On the basis of this concept, we assumed that GTV contouring using an average phase of images on 4D-CT would minimize the impact of tumor motion when they were fused with PET. Several studies have explored the use of a fixed or adaptive threshold setting for accurate measurement of tumor dimensions in thoracic cancer [7, 11, 21], but none of these studies reported comprehensive parameters such as the VR, CI or tumor length when compared with the GTVCT. It is likely that this can be attributed to the complexity of organ motion and the uncertainty of image registration. Hanna et al. [29] investigated the impact of PET/CT simulation for GTV definition in NSCLC using the concordance index (equivalent to CI in our study). The mean concordance index of their study was 0.64 and 0.57 in GTVPET-CT and GTVCT, respectively. This indicated a significant decrease in inter-observer variation by adding PET results to the GTV delineation. In another EC study, Vali et al. [21] compared GTVPET with GTVCT/EUS at the level of the esophageal tumor epicenter, and found that a threshold setting of SUV 2.5 and SUVL4σ (equal to SUV 2.4) resulted in the highest CI value (0.48 and 0.47, respectively). Gondi et al. [24] demonstrated that CI values of NSCLC and EC with the incorporation of FEG-PET and CT were 0.44 and 0.46, respectively. To the best of our knowledge, this is the first study that has compared CI values between GTVPET and GTVCT using 4D-PET/CT in contouring EC and using whole tumor volume. Our results were similar to the studies mentioned above. The CIs of our study implied an overlap of approximately 75% between the two volumes. The CI levels of SUV 40% or 50% were inferior to the other thresholds and were not ideal for auto-contouring the GTVPET. Furthermore, the VR was close to 1 at SUV 20% and SUV 2.5. It was better than the other studies with respect to the partial VR of EC [21] and the VR of NSCLC [11]. When using smaller cutoff values, such as SUV 2 or SUV 15%, for the threshold setting, more adjacent normal tissue would be included within the GTVPET. Thus, the primitive values of CI and VR were changed, but the values improved when some artifacts were corrected. However, these manual procedures were very time consuming. Our results should be interpreted keeping three limitations in mind. First, the study was based on the comparison of GTVCT and GTVPET without knowledge of the pathological information on tumor length, axial extent or real volume. Certainly, the biological volume could not be definitivelyrelated to the real tumor volume. Similarly, the GTVCT could identify areas without tumor tissue. It seems difficult to perform a direct pathological comparison from the surgical specimen because use of a neoadjuvant or definitive concurrent chemoradiotherapy while treating EC is popular [2, 30]. Second, using the averaged phase of 4D-CT images fused with the averaged PETs to delineate the GTVs is not a flawless system. This approach might provide more accurate functional images supplemental to the CT without increasing the clinical overwork during contouring; however, the impact of tumor motion from maximum intensity projection should be investigated further. In addition, PET images have lower resolution than CT images, which might limit the results of this study. Third, the sample size of this study might lead to some uncertainties. Many more cases involving a variety of tumor sites are required to clarify the association between tumor location and 4D tumor motion [27]. This study demonstrated that 4D-PET/CT is an appropriate method of contouring the GTV in radiation planning for EC. The use of threshold levels of SUV 20% or SUV 2.5 achieves the optimal correlation with tumor length, VR and CI. To assess the final treatment outcome, the benefits of RT planning using 4D-PET/CT need more clinical investigations with a large sample size and different tumor locations.
  30 in total

1.  Four-dimensional computed tomographic analysis of esophageal mobility during normal respiration.

Authors:  Edith M T Dieleman; Suresh Senan; Andrew Vincent; Frank J Lagerwaard; Ben J Slotman; John R van Sörnsen de Koste
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007-03-01       Impact factor: 7.038

Review 2.  PET-based treatment planning in radiotherapy: a new standard?

Authors:  Vincent Grégoire; Karin Haustermans; Xavier Geets; Sarah Roels; Max Lonneux
Journal:  J Nucl Med       Date:  2007-01       Impact factor: 10.057

3.  Design of 4D treatment planning target volumes.

Authors:  Eike Rietzel; Arthur K Liu; Karen P Doppke; John A Wolfgang; Aileen B Chen; George T Y Chen; Noah C Choi
Journal:  Int J Radiat Oncol Biol Phys       Date:  2006-09-01       Impact factor: 7.038

4.  Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis.

Authors:  Val Gebski; Bryan Burmeister; B Mark Smithers; Kerwyn Foo; John Zalcberg; John Simes
Journal:  Lancet Oncol       Date:  2007-03       Impact factor: 41.316

5.  18F-FDG PET definition of gross tumor volume for radiotherapy of non-small cell lung cancer: is a single standardized uptake value threshold approach appropriate?

Authors:  Kenneth J Biehl; Feng-Ming Kong; Farrokh Dehdashti; Jian-Yue Jin; Sasa Mutic; Issam El Naqa; Barry A Siegel; Jeffrey D Bradley
Journal:  J Nucl Med       Date:  2006-11       Impact factor: 10.057

6.  Pre-operative estimation of esophageal tumor metabolic length in FDG-PET images with surgical pathology confirmation.

Authors:  Marcelo Mamede; Georges El Fakhri; Paula Abreu-e-Lima; William Gandler; Vânia Nosé; Victor H Gerbaudo
Journal:  Ann Nucl Med       Date:  2007-12-25       Impact factor: 2.668

7.  Using 18F-fluorodeoxyglucose positron emission tomography to estimate the length of gross tumor in patients with squamous cell carcinoma of the esophagus.

Authors:  Xiaojun Zhong; Jinming Yu; Baijiang Zhang; Dianbin Mu; Weidi Zhang; Daotang Li; Anqin Han; Pingping Song; Hui Li; Guoren Yang; Feng-Ming Kong; Zheng Fu
Journal:  Int J Radiat Oncol Biol Phys       Date:  2008-06-04       Impact factor: 7.038

8.  Effects of respiration-averaged computed tomography on positron emission tomography/computed tomography quantification and its potential impact on gross tumor volume delineation.

Authors:  Pai-Chun Melinda Chi; Osama Mawlawi; Dershan Luo; Zhongxing Liao; Homer A Macapinlac; Tinsu Pan
Journal:  Int J Radiat Oncol Biol Phys       Date:  2008-07-01       Impact factor: 7.038

9.  Improving observer variability in target delineation for gastro-oesophageal cancer--the role of (18F)fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography.

Authors:  D Vesprini; Y Ung; R Dinniwell; S Breen; F Cheung; D Grabarz; J Kamra; K Mah; A Mansouri; G Pond; K Brock; G Darling; J Knox; M Haider; R K S Wong
Journal:  Clin Oncol (R Coll Radiol)       Date:  2008-08-27       Impact factor: 4.126

10.  Impact of manual and automated interpretation of fused PET/CT data on esophageal target definitions in radiation planning.

Authors:  Theodore S Hong; Joseph H Killoran; Marcelo Mamede; Harvey J Mamon
Journal:  Int J Radiat Oncol Biol Phys       Date:  2008-12-01       Impact factor: 7.038

View more
  12 in total

1.  Respiratory-induced errors in tumor quantification and delineation in CT attenuation-corrected PET images: effects of tumor size, tumor location, and respiratory trace: a simulation study using the 4D XCAT phantom.

Authors:  Parham Geramifar; Mojtaba Shamsaie Zafarghandi; Pardis Ghafarian; Arman Rahmim; Mohammad Reza Ay
Journal:  Mol Imaging Biol       Date:  2013-12       Impact factor: 3.488

2.  Postoperative PET/CT and target delineation before adjuvant radiotherapy in patients with oral cavity squamous cell carcinoma.

Authors:  Pinaki R Dutta; Nadeem Riaz; Sean McBride; Luc G Morris; Snehal Patel; Ian Ganly; Richard J Wong; Frank Palmer; Heiko Schöder; Nancy Lee
Journal:  Head Neck       Date:  2015-09-03       Impact factor: 3.147

3.  Motion-compensated FDG PET/CT for oesophageal cancer.

Authors:  Francine E M Voncken; Erik Vegt; Johanna W van Sandick; Jolanda M van Dieren; Cecile Grootscholten; Annemarieke Bartels-Rutten; Steven L Takken; Jan-Jakob Sonke; Jeroen B van de Kamer; Berthe M P Aleman
Journal:  Strahlenther Onkol       Date:  2021-04-07       Impact factor: 3.621

4.  Comparison of planning target volumes based on three-dimensional and four-dimensional CT imaging of thoracic esophageal cancer.

Authors:  Wei Wang; Jianbin Li; Yingjie Zhang; Qian Shao; Min Xu; Tingyong Fan; Jinzhi Wang
Journal:  Onco Targets Ther       Date:  2016-08-02       Impact factor: 4.147

5.  A comparative study of target volumes based on 18F-FDG PET-CT and ten phases of 4DCT for primary thoracic squamous esophageal cancer.

Authors:  Yanluan Guo; Jianbin Li; Peng Zhang; Yingjie Zhang
Journal:  Onco Targets Ther       Date:  2017-01-06       Impact factor: 4.147

6.  Comparative evaluation of target volumes defined by deformable and rigid registration of diagnostic PET/CT to planning CT in primary esophageal cancer.

Authors:  Yanluan Guo; Jianbin Li; Peng Zhang; Qian Shao; Min Xu; Yankang Li
Journal:  Medicine (Baltimore)       Date:  2017-01       Impact factor: 1.889

7.  Fiducial markers coupled with 3D PET/CT offer more accurate radiation treatment delivery for locally advanced esophageal cancer.

Authors:  Jasmine A Oliver; Puja Venkat; Jessica M Frakes; Jason Klapman; Cynthia Harris; Jaime Montilla-Soler; Gautamy C Dhadham; Baderaldeen A Altazi; Geoffrey G Zhang; Eduardo G Moros; Ravi Shridhar; Sarah E Hoffe; Kujtim Latifi
Journal:  Endosc Int Open       Date:  2017-05-31

8.  The use of PET/CT in radiotherapy planning: contribution of deformable registration.

Authors:  Ela Delikgoz Soykut; Esat Mahmut Ozsahin; Yildiz Yukselen Guney; Suheyla Aytac Arslan; Ozlem Derinalp Or; Muzaffer Bedri Altundag; Gamze Ugurluer; Pelagia G Tsoutsou
Journal:  Front Oncol       Date:  2013-04-12       Impact factor: 6.244

Review 9.  The application of functional imaging techniques to personalise chemoradiotherapy in upper gastrointestinal malignancies.

Authors:  J M Wilson; M Partridge; M Hawkins
Journal:  Clin Oncol (R Coll Radiol)       Date:  2014-07-04       Impact factor: 4.126

10.  Respiratory-gated (4D) contrast-enhanced FDG PET-CT for radiotherapy planning of lower oesophageal carcinoma: feasibility and impact on planning target volume.

Authors:  Andrew Scarsbrook; Gillian Ward; Patrick Murray; Rebecca Goody; Karen Marshall; Garry McDermott; Robin Prestwich; Ganesh Radhakrishna
Journal:  BMC Cancer       Date:  2017-10-04       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.